Clinical Trial Update: Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia [NA]

View source ↗

Summary

A terminated clinical trial evaluated contrast-enhanced spectral mammography to predict upgrade rates in biopsy-proven atypical ductal hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Ductal Hyperplasia

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Atypical Ductal Hyperplasia | NA | Status: TERMINATED | Results posted: 2020-02-11